Neoadjuvant therapy as a platform for drug development and approval in breast cancer
about
Cytotoxic and targeted therapy for hereditary cancersNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabAccurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersRecent developments and translational aspects in targeted therapy for metastatic breast cancerERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response.Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteriaImproved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapyUltrasound-Guided Diffuse Optical Tomography for Predicting and Monitoring Neoadjuvant Chemotherapy of Breast Cancers: Recent Progress.Can immunity to breast cancer eliminate residual micrometastases?Precision medicine and personalized breast cancer: combination pertuzumab therapy.The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.Pertuzumab for the treatment of breast cancer.Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers.AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials.Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.Effect of Body Mass Index- and Actual Weight-Based Neoadjuvant Chemotherapy Doses on Pathologic Complete Response in Operable Breast Cancer.Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility.Clinical and Molecular Methods in Drug Development: Neoadjuvant Systemic Therapy in Breast Cancer as a Model.
P2860
Q26739366-FA2001A6-59A2-4B23-BB4C-F3CF7551B44FQ26764879-593E4EC4-2A52-4379-9E09-42D43ADC3194Q28069856-915AAEC2-AB40-48E8-A7D1-F834B3E1135DQ28072755-C9BF4800-32A0-4E7A-A9CB-A023C2C6B7B8Q33601653-2A1D1CF3-3977-4709-A21B-FFBE41B19892Q33739692-992FFF79-4F8A-4399-AA27-2F05DCB5FA17Q34232366-E8792094-EF74-41BD-8381-A4E7007F2406Q35000348-CDBEA725-0550-497D-AEA7-BE9CC2C00781Q35789363-DB1DEAB7-D8E2-401B-AC82-C8D34F231817Q36150390-A2CB3116-DDA3-450F-9DBA-E8F9C89687A8Q36272043-73C22E97-3EE6-473E-BCA3-0DF84924FC09Q36619000-DDC0A53C-BED0-4EE5-A705-D3F94BEEB9D0Q36759772-30BE280D-2489-4808-AC14-01715D2813C2Q37324851-249D6B4E-2DBD-40F8-8E1F-74EA6C547DB2Q37396270-D9F452BD-FACE-486B-90C1-FD132136DA1CQ37687975-7234A044-01AF-429A-B07A-A4761E8F852FQ38192017-9C0726FB-703E-4C41-ABE6-F1DEC58FED89Q38214802-3442BD1F-5C13-4C4D-AA08-57B97B982C85Q38219674-8BC21D5C-776A-43C4-9BBF-DC41E16210D1Q38389226-F7ECDB67-8493-4D81-BD2A-71532F22C296Q38648335-696474A2-E785-48C3-9E7E-C4751C8E0212Q38693888-CEF70D6A-F10A-4805-A59D-559037408B8EQ38883281-4CE5BC7B-A47B-4E18-84A6-E08DD44E22CBQ47288520-9CB106CD-2BAA-4329-8572-6314B31C2E20Q50905729-B05D2471-4668-4335-A362-07C973FDBE97Q52984715-1869E7CC-B7FC-4D05-A60B-846B52504B5D
P2860
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@ast
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@en
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@nl
type
label
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@ast
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@en
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@nl
prefLabel
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@ast
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@en
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@nl
P3181
P1476
Neoadjuvant therapy as a platform for drug development and approval in breast cancer
@en
P2093
P304
P3181
P356
10.1158/1078-0432.CCR-13-0916
P407
P577
2013-12-01T00:00:00Z